Decisive In Vivo Data for Cell Therapy Candidate Selection.
What are the primary endpoints in a CAR-NK vs. CAR-T efficacy study?
Primary endpoints typically include tumor growth inhibition (TGI), overall survival, and quantification of tumor burden via bioluminescence imaging (BLI). Secondary and exploratory endpoints often involve flow cytometry analysis of peripheral blood or tumor tissue to assess cell persistence, phenotype, and exhaustion markers.
How do you model the tumor microenvironment in these xenograft studies?
To better reflect the clinical setting, we utilize B-cell lymphoma cell lines known for aggressive growth and establish subcutaneous or disseminated disease models. For specific programs, co-implantation with stromal or other immune cell types can be employed to create a more complex and representative tumor microenvironment (TME).
What are the key safety readouts beyond efficacy?
Key safety assessments include monitoring for signs of Graft-versus-Host Disease (GvHD), regular body weight measurements, and clinical observations. We also perform terminal collection of key tissues for histology and analysis of non-target tissue biodistribution to evaluate potential off-tumor activity.
How does Franklin Biolabs ensure GxP compliance for pharmacology studies?
All studies are conducted within a robust quality framework adhering to GxP principles. This includes comprehensive standard operating procedures (SOPs), rigorous data integrity protocols, quality assurance oversight, and detailed study reports designed to support regulatory submissions.
Direct, head-to-head in vivo comparison is required to de-risk the clinical translation of CAR-NK and CAR-T cell therapy candidates. While CAR-NK constructs offer potential safety advantages, including a reduced risk of GvHD, CAR-T therapies have more established clinical data regarding long-term persistence. The optimal platform depends entirely on the specific target antigen, indication, and desired therapeutic window. Franklin Biolabs provides robust, well-characterized B-cell lymphoma xenograft models to generate the comparative pharmacology data needed for confident candidate selection and IND filing.
